irofulven has been researched along with serine in 1 studies
| Studies (irofulven) | Trials (irofulven) | Recent Studies (post-2010) (irofulven) | Studies (serine) | Trials (serine) | Recent Studies (post-2010) (serine) |
|---|---|---|---|---|---|
| 99 | 22 | 7 | 23,914 | 115 | 6,084 |
| Protein | Taxonomy | irofulven (IC50) | serine (IC50) |
|---|---|---|---|
| Acetylcholinesterase | Electrophorus electricus (electric eel) | 0.015 | |
| Cholinesterase | Equus caballus (horse) | 0.016 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burks, J; Cunningham, C; Mikell, C; Reed, E; Van Laar, ES; Wang, J; Wang, W; Wang, Y; Waters, SJ; Wiltshire, T | 1 |
1 other study(ies) available for irofulven and serine
| Article | Year |
|---|---|
ATM-dependent CHK2 activation induced by anticancer agent, irofulven.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Chromosomal Proteins, Non-Histone; DNA-Binding Proteins; Female; Humans; Nuclear Proteins; Ovarian Neoplasms; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; S Phase; Serine; Sesquiterpenes; Signal Transduction; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2004 |